Welcome to the Evexia Diagnostics COVID-19 Repository Page.
While the global health crisis concerning the SARS-CoV-2 pandemic continues to unfold, Evexia’s focus and commitment to offering high-quality, state-of-the-art testing at affordable prices are becoming increasingly vital. Our current goal is to increase the availability of fast and reliable COVID-19 testing to help mitigate the current spread of the virus. We also recognize that there is a lack of proper guidance on what testing is most appropriate. As a result, we have created this resource dedicated to providing easy access to insightful information, cost-effective and reliable testing options, as well as recommendations for nutraceutical support.
Order COVID-19 Testing
Review our full offering of the most advanced
COVID-19 testing for every stage of the virus.
Learn more about COVID-19
Learn about the latest COVID-19 facts and testing.
COVID-19 TESTING GUIDANCE
Available SARS CoV-2 (COVID-19) Testing
Evexia Diagnostics now offers COVID-19 testing options for ALL of our clients. Each of our trusted laboratory partners is CLIA-Certified and all testing is performed at High-Complexity laboratory facilities.
For additional clarification regarding the best testing option for your patients, please utilize our COVID-19 Interactive Testing Guidance, located here.
Diagnostic Testing
Surveillance Testing
To learn more about Antibody Testing – Click Here • To learn more about Antibodies – Click Here
SARS CoV-2
Stool PCR Test
COVID-19 Antibody Testing
- NOT A DIAGNOSTIC TEST FOR CURRENT COVID-19 INFECTION
- Detects body’s immune response to COVID-19 by measuring specific antibodies associated with COVID-19 (SARS-CoV-2)
- Any positive results should be confirmed using the COVID-19 PCR Test.
- Follow-up testing with the COVID-19 PCR Test should also be considered to rule out infection in individuals with a negative COVID-19 Antibody Test who exhibit symptoms of COVID-19
- Blood draw required
Please note that negative results do not rule out SARS-CoV-2 infection. Results from the COVID-19 Antibody Test should not be used as the sole basis for diagnosis or exclusion of a SARS-CoV-2 infection. This COVID-19 antibody test is based on a unique fragment of the nucleoprotein from COVID-19 (SARS-Cov-2). Antibodies, IgM and IgG, generated against this fragment have been demonstrated NOT to cross-react with other viruses, including other coronavirus strains. Follow-up testing with the COVID-19 PCR test should be considered to rule out infection in individuals with negative serological results who exhibit symptoms of COVID-19.This test has not been reviewed by the FDA.Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
COVID-19 Antibody Testing is available to all Evexia clients, including non-licensed clinicians. For all non-licensed client orders, a $15 physician network fee will apply and our phlebotomy network must be utilized for sample collection and shipping.
ANTIBODY TYPES:
IgA –
- IgA antibodies are found in saliva, tears, and blood.
- IgA antibodies protect bodily surfaces that are exposed to outside foreign substances and are found in areas of the body such as the nose, breathing passages, digestive tract, ears, and eyes.
- About 10% to 15% of the antibodies present in the body are IgA antibodies.
- A small number of people do not make IgA antibodies.
IgG –
- IgG antibodies are found in all body fluids.
- IgG antibodies are the smallest but most common antibody (75% to 80%).
- IgG antibodies are very important in fighting bacterial and viral infections.
- IgG antibodies are the only type of antibody that can cross the placenta in a pregnant woman to help protect the fetus.
IgM –
- IgM antibodies are found in blood and lymph fluid and are the first type of antibody made in response to an infection.
- IgM antibodies also cause other immune system cells to destroy foreign substances.
- IgM antibodies are the largest antibody and make up about 5% to 10% of all the antibodies in the body.
Evexia Diagnostics does not accept any form of insurance nor do we have the ability to seek third-party reimbursement. We are offering this test as a convenience to our clients and their patients, who may not be able or may choose not to travel to a location where the test can be charged to a third-party. The fees charged by Evexia to our clients for the COVID-19 test are a reflection of our cost related to the acquisition and distribution of the COVID-19 test and supplies. Anyone who is symptomatic and/or who meets the CDC’s guidelines for testing has the option of receiving the test for free, but they would need to locate a testing facility (clinic, drive-thru or hospital) that is able to seek 3rd-party reimbursement and have the testing done there.
THE EVEXIA WEBINAR SERIES – SPECIAL EDITION
David M. Brady, ND, DC, CCN, DACBN, IFMCP, FACN
Chief Medical Officer
Diagnostic Solutions Laboratory
Evexia Diagnostics is excited to present a special edition webinar with Dr. David Brady from Diagnostic Solutions Laboratory. The topic will be COVID-19: What we know now, and making informed choices moving forward.
Disclaimer: This webinar is for professional educational purposes only. Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.
Wayne L. Sodano, DC, DABCI, DACBN, CFMP, CIHP, BCTN
Director of Clinical Support and Education
Evexia Diagnostics
Contributors:
Kevin K. Bodling, DC, DACBN, DABCI
President & Chief Executive Officer
Evexia Diagnostics
Will Blankenship, MD
Chief Medical Officer
Evexia Diagnostics
Evexia Diagnostics is pleased to present “COVID-19: Immune Preparedness Against An Unfolding Pandemic”. This video serves as a follow up to our previous COVID-19 webinar and provides some updated information, but more importantly, offers an in-depth look at avenues to improve immune function and help prevent infection.
Disclaimer: This webinar is for professional educational purposes only. Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.
Wayne L. Sodano, DC, DABCI, DACBN, CFMP, CIHP, BCTN
Director of Clinical Support and Education
Evexia Diagnostics
Contributors:
Kevin K. Bodling, DC, DACBN, DABCI
President & Chief Executive Officer
Evexia Diagnostics
Will Blankenship, MD
Chief Medical Officer
Evexia Diagnostics
The underlying importance of a properly functioning immune system is highlighted as global concerns continue to grow regarding the spread of COVID-19 (Coronavirus Disease). Evexia Diagnostics is proud to offer an educational webinar for you to learn more about the natural avenues and precautionary measures available to help safeguard against infection and to help ensure that your patient’s immune system is able to provide an adequate response to this emerging threat.
Disclaimer: This webinar is for professional educational purposes only. Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.
EVEXIA TESTING AND NUTRACEUTICAL RECOMMENDATIONS FOR BUILDING AND SUPPORTING A STRONG IMMUNE SYSTEM
Recommended Evexia Panels
Complete Wellness Panel
- Apolipoprotein B
- Bilirubin, Direct
- Complete Blood Count (CBC) With Differential
- Comprehensive Metabolic Panel (CMP-14)
- Cortisol
- C-Reactive Protein (CRP), High Sensitivity
- Dehydroepiandrosterone (DHEA) Sulfate
- Ferritin + Iron + Total Iron-binding Capacity (TIBC)
- Fibrinogen Activity (Factor I Activity)
- Gamma-Glutamyl Transferase (GGT)
- Hemoglobin (Hb) A1c With eAG
- Homocyst(e)ine
- Insulin
- Lactic Acid Dehydrogenase (LD/LDH)
- Lipid Panel + VLDL + TC/HDL Ratio + LDL/HDL Ratio + CHD Risk
- Lipoprotein(a)
- Magnesium
- Phosphorus
- Thyroid Profile II, Comprehensive (FTI; T3 Uptake; TSH; T4; T3)
- Uric Acid
- Vitamin D, 25-Hydroxy
Comprehensive Wellness Panel
- Apolipoprotein B
- Bilirubin, Direct
- Coenzyme Q10, Total (CoQ10)
- Complete Blood Count (CBC) With Differential
- Comprehensive Metabolic Panel (CMP-14)
- Cortisol
- C-Reactive Protein (CRP), High Sensitivity
- Deaminated Gliadin Antibodies, IgA & IgG
- Dehydroepiandrosterone (DHEA) Sulfate
- Estradiol (E2)
- F2-Isoprostane/Creatinine Ratio
- Ferritin + Iron + Total Iron-binding Capacity (TIBC)
- Fibrinogen Activity (Factor I Activity)
- Folate, RBC
- Gamma-Glutamyl Transferase (GGT)
- Hemoglobin (Hb) A1c With eAG
- Homocyst(e)ine
- Insulin
- Iodine, Serum or Plasma
- Lactic Acid Dehydrogenase (LD/LDH)
- Lipid Panel + VLDL + TC/HDL Ratio + LDL/HDL Ratio + CHD Risk
- Lipoprotein(a)
- Magnesium
- Magnesium, RBC
- Omega 3 and 6 Fatty Acids
- Phosphorus
- Testosterone Profile (Bioactive + Total), LC/MS-MS
- Thyroid Profile II, Comprehensive (FTI; T3 Uptake; TSH; T4; T3)
- Uric Acid
- Urinalysis, Complete with Microscopic Examination
- Vitamin B12 (Cobalamin)
- Vitamin D, 25-Hydroxy
- Zinc, RBC
Recommended Individual Tests
- Complete Blood Count (CBC) With Differential
- Comprehensive Metabolic Panel (CMP-14)
- Cortisol
- Eosinophil Cationic Protein (ECP) / Ribonuclease 3
- F2-Isoprostane
- Glutathione
- Immunoglobulins, Quantitative, IgA, IgG, IgM
- Influenza A and B Antibodies
- Interleukin-02 (IL-2)
- Mannose-binding Lectin (MBL)
- Myeloperoxidase (MPO)
- Natural Killer Cell and Activated T-Cell Profile/IL-2r
- Neopterin, Urin
- Respiratory Pathogen Profile, Comprehensive, PCR
- Tumor Necrosis Factor-α
- Vitamin A (Retinol)
- Vitamin C (Ascorbic Acid)
- Vitamin C (With Dilution)
- Zinc, RBC
Recommended Specialty Tests
- GDX- ImmunoGenomic Profile
- GDX- ION Profile
- GDX- NutrEval
- GDX- ONE (Optimal Nutritional Evaluation) FMV
- GDX- Oxidative Stress Analysis 2.0
- Spectracell- Micronutrient Test
Recommended Evexia Nutraceuticals and Supplements
Currently there are no pharmaceutical or natural medicines approved by the FDA to specifically treat COVID-19.
Immune Essentials Plus
More information >>
Silver Max
More information >>
Zinc Max
More information >>
Essential Protein BEEF Plus
More information >>
C+Flavinoids
More information >>
Multi Complex Plus
More information >>
Max Antiox Complete
More information >>
S-Acetyl Glutathione
Complete
More information >>
Monolaurin or Monolauric Acid (MLA)
More information
Monolaurin has demonstrated antibacterial, antiviral, and antimicrobial properties. Studies have also shown that Monolauric Acid can disintegrate the protective viral envelope, thereby preventing it from attaching and entering host cells, and ultimately kill the virus. MLA can also help the immune system recognize a pathogen by increasing immunogenicity creating an additional antigenic epitope that can be recognized by T-helper cells. This dramatically improves the immune response time and allows for a quicker resolution of infection.
SARS CoV-2 Diagnostic Respiratory PCR Test
- Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
- Detects the presence of SARS-CoV-2 viral RNA in respiratory samples
- Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
- Utilizes Nasal or Nasopharyngeal swab
- Rapid 24-48 hour turnaround time kit
SARS-CoV-2 IgG Antibody Test (LabCorp)
- Detects the body’s immune response to SARS-CoV-2 by measuring specific IgM and IgG antibodies associated with SARS-CoV-2
- Can determine past infection and possible concomitant immunity
- Cost-effective option, if an active infection is not a concern
- Can be collected at over 2000 LabCorp Patient Service Centers(PSCs) across the country
- 1-3 day turnaround time
SARS CoV-2 Stool PCR Test
- NOT A DIAGNOSTIC TEST FOR CURRENT COVID-19 INFECTION
- Detects SARS-CoV-2 viral RNA in stool using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
- SARS-CoV-2 in the stool may be found in up to 53.4% of COVID-19 patients and can be detected in the stool for up to 5 weeks after clearance from the respiratory tract
- Stool kit
- 24-hour turnaround time
Not approved or evaluated by the FDA. This test is for investigational or Research Use Only (RUO).
Please note that the SARS-CoV-2 Stool Analysis is not diagnostic of COVID-19. COVID-19 can only be properly diagnosed and confirmed using the nasal COVID-19 PCR Test.
SARS CoV-2 Diagnostic Salivary PCR Test
- Diagnostic test for SARS-CoV-2, using real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology
- Detects the presence of SARS-CoV-2 viral RNA in salivary samples
- Determines current SARS-CoV-2 infection but does not indicate past infection or immunity
- Utilizes simple at-home salivary collection
- Rapid 24-48 hour turnaround time
The United States FDA has provided emergency use authorization (EUA) of this test for testing human upper and lower respiratory specimens
SURVEILLANCE COVID-19 Immune Response Panel
Serum test that measures both nucleocapsid (N-protein) and S-RBD antibodies
The COVID-19 Immune Response Panel measures both nucleocapsid (N-protein) and S-RBD antibodies. N-protein antibodies do not rise in response to COVID-19 S-RBD vaccinations. The combined serum IgM/IgG tests measure the body’s response to COVID-19 nucleocapsid (N) and spike protein receptor-binding domain (S-RBD) exposure. The N and S-RBD antibodies’ combination assay has a > 99% positive and negative predictive value 15 days after COVID-19 exposure. This test does not differentiate between IgM and IgG; studies indicate that joint testing is as or more reliable than individual IgM and IgG testing in confirming COVID-19 exposure.
SURVEILLANCE COVID-19 Vaccine Response Screen
Serum test which measures only the antibody response to the S-RBD protein
The COVID-19 Vaccine Response Screen measures only the antibody response to the S-RBD protein. Once the baseline immune response has been established, this test can be used post-vaccination to evaluate immune status. The average time for seroconversion has been estimated at 2-3 weeks. However, the strongest antibody responses will likely be seen after the second vaccine dose 6-8 weeks after the first inoculation.
